Adlai Nortye Group (ANL) vs MoonLake Immunotherapeutics (MLTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed MoonLake Immunotherapeutics (MLTX) over the past year, gaining 796.5% versus a gain of 16.1%. Adlai Nortye Group is the larger company by market cap ($998.8 million vs $900.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | MLTX |
|---|---|---|
| Share price | $15.51 | $10.58 |
| Market cap | $998.81M | $900.43M |
| 1-day change | +10.39% | -1.76% |
| YTD return | +992.25% | -18.29% |
| 1-year return | +796.53% | +16.06% |
| 5-year return | — | +8.57% |
| EPS (TTM) | $-0.66 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $23.29 |
| 52-week low | $0.879 | $8.80 |
| Distance from 52-week high | -10.09% | -54.57% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +90.20% | +169.75% |
| Average volume | 175.26K | 1.47M |
| Shares outstanding | 58.73M | 85.11M |
| Employees | 109 | 130 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed MLTX by 780.5 percentage points over the past year.
- The two companies sit in different sectors: Adlai Nortye Group in Healthcare and MoonLake Immunotherapeutics in Health Care.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Healthcare · Biotechnology · 109 employees
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
ANL vs MLTX FAQ
Which is bigger, Adlai Nortye Group or MoonLake Immunotherapeutics?
Adlai Nortye Group (ANL) is larger, with a market capitalization of $998.81M compared with $900.43M for MoonLake Immunotherapeutics (MLTX).
Which stock has performed better over the past year, ANL or MLTX?
ANL returned +796.53% over the past 12 months, compared with +16.06% for MLTX (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and MoonLake Immunotherapeutics in the same industry?
No. Adlai Nortye Group is in the Healthcare sector, while MoonLake Immunotherapeutics is in Health Care.